Correlation Between Forte Biosciences and Indaptus Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Forte Biosciences and Indaptus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Forte Biosciences and Indaptus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Forte Biosciences and Indaptus Therapeutics, you can compare the effects of market volatilities on Forte Biosciences and Indaptus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Forte Biosciences with a short position of Indaptus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Forte Biosciences and Indaptus Therapeutics.

Diversification Opportunities for Forte Biosciences and Indaptus Therapeutics

-0.21
  Correlation Coefficient

Very good diversification

The 3 months correlation between Forte and Indaptus is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Forte Biosciences and Indaptus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Indaptus Therapeutics and Forte Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Forte Biosciences are associated (or correlated) with Indaptus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Indaptus Therapeutics has no effect on the direction of Forte Biosciences i.e., Forte Biosciences and Indaptus Therapeutics go up and down completely randomly.

Pair Corralation between Forte Biosciences and Indaptus Therapeutics

Given the investment horizon of 90 days Forte Biosciences is expected to under-perform the Indaptus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Forte Biosciences is 1.36 times less risky than Indaptus Therapeutics. The stock trades about -0.04 of its potential returns per unit of risk. The Indaptus Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  185.00  in Indaptus Therapeutics on March 27, 2024 and sell it today you would earn a total of  37.00  from holding Indaptus Therapeutics or generate 20.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy99.68%
ValuesDaily Returns

Forte Biosciences  vs.  Indaptus Therapeutics

 Performance 
       Timeline  
Forte Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Forte Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Indaptus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Indaptus Therapeutics is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors.

Forte Biosciences and Indaptus Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Forte Biosciences and Indaptus Therapeutics

The main advantage of trading using opposite Forte Biosciences and Indaptus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Forte Biosciences position performs unexpectedly, Indaptus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will offset losses from the drop in Indaptus Therapeutics' long position.
The idea behind Forte Biosciences and Indaptus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamental Analysis
View fundamental data based on most recent published financial statements